Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06818643

A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)

Researchers are looking for new ways to treat people with certain advanced solid tumors. Advanced means the cancer has spread to other parts of the body and cannot be removed with surgery. Solid tumors are cancers mostly in body organs and tissues, not in the blood or other body liquids. The main goal of this study is to learn about the safety of MK-3120 and if people tolerate it.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Advanced Solid Tumors Malignant Neoplasm Neoplasms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1 / Phase 2

Primary location

Bradford Hill Centro de Investigaciones Clinicas ( Site 0030), Santiago, Region M. de Santiago, Chile

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Has a confirmed advanced (unresectable and/or metastatic) solid tumor and has received or been intolerant to all available treatments
  • If human immunodeficiency virus (HIV) positive, has well controlled HIV on antiretroviral therapy (ART)
  • If hepatitis B surface antigen (HBsAg) positive, must have received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV viral load
  • If hepatitis C virus (HCV) infected, must have undetectable HCV viral load

Exclusion criteria

  • Has active inflammatory bowel disease requiring immunosuppressive medication or previous history of inflammatory bowel disease
  • Has uncontrolled significant cardiovascular disease or cerebrovascular disease
  • Has history of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or severe corneal disease that prevents/delays corneal healing
  • Has pleural effusion, ascites, and/or pericardial effusion that are symptomatic or require repeated drainage
  • Is HIV-positive and has a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease
  • Known additional malignancy that is progressing or has required active treatment within the past 2 years
  • Known active central nervous system (CNS) metastases and/or carcinomatous meningitis
  • Active infection requiring systemic therapy, with exceptions
  • History of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease
  • Has HBV or HCV infection

Treatment and study plan

MK-3120

Biological

IV infusion

Other names: SKB410

Primary outcomes

  1. Number of Participants Who Experience an Adverse Event (AE)

    Time frame: Up to approximately 43 months

    An AE is defined as any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experience at least one AE will be presented.

  2. Number of Participants Who Discontinue Study Treatment Due to an AE

    Time frame: Up to approximately 42 months

    An AE is defined as any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who discontinue study treatment due to an AE will be presented.

Secondary outcomes

  1. Objective Response Rate (ORR) Per Response Evaluation Criteria In Solid Tumors 1.1 (RECIST 1.1) as Assessed by the Investigator

    Time frame: Up to approximately 72 months

    ORR is defined as the percentage of participants who had a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) as assessed by the investigator per RECIST 1.1.

  2. Duration Of Response (DOR) Per RECIST 1.1 as Assessed by the Investigator

    Time frame: Up to approximately 72 months

    For participants who demonstrate a confirmed CR (disappearance of all target lesions) or confirmed PR (at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR is defined as the time from first documented evidence of CR or PR until progressive disease (PD) or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. DOR as assessed by the investigator per RECIST 1.1 will be presented.

  3. Progression-free Survival (PFS) Per RECIST 1.1 as Assessed by the Investigator

    Time frame: Up to approximately 72 months

    PFS is defined as the time from the first dose of study treatment to the first documented PD or death due to any cause, whichever occurs first will be assessed by the investigator using RECIST 1.1. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. PFS as assessed by the investigator per RECIST 1.1 will be presented.

  4. Overall Survival (OS) Per RECIST 1.1 as Assessed by the Investigator

    Time frame: Up to approximately 72 months

    OS is defined as the time from the first dose of study treatment to death due to any cause as assessed by the investigator per RECIST 1.1 will be presented.

  5. Area Under the Concentration-Time Curve (AUC) of MK-3120 Antibody-Drug Conjugate (ADC)

    Time frame: At specified time points up to approximately 43 months

    Blood samples will be collected to determine the AUC of MK-3120 ADC.

  6. AUC of MK-3120 Total Antibody (TAb)

    Time frame: At specified time points up to approximately 43 months

    Blood samples will be collected to determine the AUC of MK-3120 TAb

  7. AUC of MK-3120 Free Payload

    Time frame: At specified time points up to approximately 43 months

    Blood samples will be collected to determine the AUC of MK-3120 free payload.

  8. Maximum Concentration (Cmax) of MK-3120 ADC

    Time frame: At specified time points up to approximately 43 months

    Blood samples will be collected to determine the Cmax of MK-3120 ADC.

  9. Cmax of MK-3120 TAb

    Time frame: At specified time points up to approximately 43 months

    Blood samples will be collected to determine the Cmax of MK-3120 TAb.

  10. Cmax of MK-3120 Free Payload

    Time frame: At specified time points up to approximately 43 months

    Blood samples will be collected to determine the Cmax of MK-3120 free payload.

  11. Minimum Concentration (Cmin) of MK-3120 ADC

    Time frame: At specified time points up to approximately 43 months

    Blood samples will be collected to determine the Cmin of MK-3120 ADC.

  12. Cmin of MK-3120 TAb

    Time frame: At specified time points up to approximately 43 months

    Blood samples will be collected to determine the Cmin of MK-3120 TAb.

  13. Cmin of MK-3120 Free Payload

    Time frame: At specified time points up to approximately 43 months

    Blood samples will be collected to determine the Cmin of MK-3120 free payload.

Study contacts

Contact information is provided by the study sponsor or research team.

Toll Free Number

CONTACT

[email protected]

1-888-577-8839

Sponsors and collaborators

Lead sponsor

Merck Sharp & Dohme LLC

Industry

Registry information

Official study title

A Phase 1/2 Open-label Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors

Important dates

Study start
2025
Primary completion
2028
Study completion
2031
First posted
Feb 10, 2025
Registry last updated
Jul 27, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.